These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18406786)

  • 1. Vanadium compounds biological actions and potential as pharmacological agents.
    Tsiani E; Fantus IG
    Trends Endocrinol Metab; 1997 Mar; 8(2):51-8. PubMed ID: 18406786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multifunctional actions of vanadium compounds on insulin signaling pathways: evidence for preferential enhancement of metabolic versus mitogenic effects.
    Fantus IG; Tsiani E
    Mol Cell Biochem; 1998 May; 182(1-2):109-19. PubMed ID: 9609120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulino-mimetic and anti-diabetic effects of vanadium compounds.
    Srivastava AK; Mehdi MZ
    Diabet Med; 2005 Jan; 22(1):2-13. PubMed ID: 15606684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vanadium salts as insulin substitutes: mechanisms of action, a scientific and therapeutic tool in diabetes mellitus research.
    Sekar N; Li J; Shechter Y
    Crit Rev Biochem Mol Biol; 1996 Dec; 31(5-6):339-59. PubMed ID: 8994801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vanadium compounds for the treatment of human diabetes mellitus: A scientific curiosity? A review of thirty years of research.
    Domingo JL; Gómez M
    Food Chem Toxicol; 2016 Sep; 95():137-41. PubMed ID: 27417449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arylalkylamine vanadium salts as new anti-diabetic compounds.
    Zorzano A; Palacín M; Marti L; García-Vicente S
    J Inorg Biochem; 2009 Apr; 103(4):559-66. PubMed ID: 19246098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vanadium Compounds as PTP Inhibitors.
    Irving E; Stoker AW
    Molecules; 2017 Dec; 22(12):. PubMed ID: 29257048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of vanadium action: insulin-mimetic or insulin-enhancing agent?
    Cam MC; Brownsey RW; McNeill JH
    Can J Physiol Pharmacol; 2000 Oct; 78(10):829-47. PubMed ID: 11077984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vanadium in Biological Action: Chemical, Pharmacological Aspects, and Metabolic Implications in Diabetes Mellitus.
    Treviño S; Díaz A; Sánchez-Lara E; Sanchez-Gaytan BL; Perez-Aguilar JM; González-Vergara E
    Biol Trace Elem Res; 2019 Mar; 188(1):68-98. PubMed ID: 30350272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like effects of vanadium: basic and clinical implications.
    Goldwaser I; Gefel D; Gershonov E; Fridkin M; Shechter Y
    J Inorg Biochem; 2000 May; 80(1-2):21-5. PubMed ID: 10885459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vanadium compounds--a new class of therapeutic agents for the treatment of diabetes mellitus].
    Beliaeva NF; Gorodetskiĭ VK; Tochilkin AI; Golubev MA; Semenova NV; Kovel'man IR
    Vopr Med Khim; 2000; 46(4):344-60. PubMed ID: 11075417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Insulin-mimetic property of vanadium compounds].
    Korbecki J; Baranowska-Bosiacka I; Gutowska I; Chlubek D
    Postepy Biochem; 2016; 62(1):60-65. PubMed ID: 28132446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of vanadium in the management of diabetes.
    Brichard SM; Henquin JC
    Trends Pharmacol Sci; 1995 Aug; 16(8):265-70. PubMed ID: 7482987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like actions of vanadate are mediated in an insulin-receptor-independent manner via non-receptor protein tyrosine kinases and protein phosphotyrosine phosphatases.
    Shechter Y; Li J; Meyerovitch J; Gefel D; Bruck R; Elberg G; Miller DS; Shisheva A
    Mol Cell Biochem; 1995 Dec 6-20; 153(1-2):39-47. PubMed ID: 8927046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential use of vanadium compounds in therapeutics.
    Barrio DA; Etcheverry SB
    Curr Med Chem; 2010; 17(31):3632-42. PubMed ID: 20846114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicology of vanadium compounds in diabetic rats: the action of chelating agents on vanadium accumulation.
    Domingo JL; Gomez M; Sanchez DJ; Llobet JM; Keen CL
    Mol Cell Biochem; 1995 Dec 6-20; 153(1-2):233-40. PubMed ID: 8927043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies.
    Goldfine AB; Patti ME; Zuberi L; Goldstein BJ; LeBlanc R; Landaker EJ; Jiang ZY; Willsky GR; Kahn CR
    Metabolism; 2000 Mar; 49(3):400-10. PubMed ID: 10726921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vanadium and tungsten derivatives as antidiabetic agents: a review of their toxic effects.
    Domingo JL
    Biol Trace Elem Res; 2002 Aug; 88(2):97-112. PubMed ID: 12296430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Molecular Mechanisms and Rational Design of Anti-Diabetic Vanadium Compounds.
    Niu X; Xiao R; Wang N; Wang Z; Zhang Y; Xia Q; Yang X
    Curr Top Med Chem; 2016; 16(8):811-22. PubMed ID: 26311429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vanadium chemistry and biochemistry of relevance for use of vanadium compounds as antidiabetic agents.
    Crans DC; Mahroof-Tahir M; Keramidas AD
    Mol Cell Biochem; 1995 Dec 6-20; 153(1-2):17-24. PubMed ID: 8927035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.